Showing 2031-2040 of 10039 results for "".
From the Neck Down
https://practicaldermatology.com/topics/practice-management/from-the-neck-down/20781/Exploring other uses for Allergan's KybellaUpdate: Oral Therapies for the Treatment of BCC
https://practicaldermatology.com/topics/practice-management/update-oral-therapies-for-the-treatment-of-bcc/21132/With the recent FDA approval of a new oral agent, the therapeutic outlook for BCC is both more diverse and promising.Recently Passed Law Clears Way for New Sunscreen Ingredients
https://practicaldermatology.com/topics/skin-cancer-photoprotection/recently-passed-law-clears-way-for-new-sunscreen-ingredients/21232/By forcing the FDA to clear its backlog of sunscreen ingredients pending review, The Sunscreen Innovation Act is a major win for UV protection efforts.Melanoma Treatment Landscape Evolves
https://practicaldermatology.com/topics/skin-cancer-photoprotection/melanoma-treatment-landscape-evolves/21314/The first agent to target the PD-1 pathway, pembrolizumab may prolong life expectancy in some patients.Pipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investigEvent Marketing: Strategies to Spotlight Your Practice and Cosmetic Services
https://practicaldermatology.com/topics/practice-management/event-marketing-strategies-to-spotlight-your-practice-and-cosmetic-services/20335/The notion of hosting an event can be overwhelming, but many practices find the endeavor worthwhile. Ahead are tips for success—and a word of caution.Verrucous Psoriasis
https://practicaldermatology.com/topics/psoriasis/verrucous-psoriasis/27148/Verrucous psoriasis (VP) is a rare subtype of psoriasis most commonly affecting middle-aged to older adults, with fewer than 35 reported cases within the current literature. It is characterized by symmetric wart-like, hyperkeratotic, papillomatous plaques. Treatment options are limited and variable,A First Look at Rotational Fractional Resection
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-first-look-at-rotational-fractional-resection/20383/A new technology offers a fresh approach to treatment of submental contouring.New Drugs in Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-drugs-in-psoriasis/20933/The last two years have seen a number of new drugs approved to treat psoriasis—from targeted biologics to new topicals.Triple Threat
https://practicaldermatology.com/topics/general-topics/triple-threat/20629/In defense of the Aron Regimen for resistant atopic dermatitis.